https://www.reuters.com/business/healthcare-pharmaceuticals/mesoblast-soars-us-fdas-nod-review-lead-drug-candidate-2023-03-08/#:~:text=The%20brokerage%20said%20it%20expects,%241.140%20earlier%20in%20the%20session.
Brokerage Jefferies said it expects "significant" U.S. sales of the drug (nah, therapy) in fiscal 2024.
PS: I will be adding on any pull backs.
This post is not to be construed as investment advice because it is not meant to be.
https://www.reuters.com/business/healthcare-pharmaceuticals/mesob...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.06 | $4.942M | 4.613M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 70659 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 43531 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |